|
**Overview**: HOMA-IR Panel**Introduction**: The HOMA-IR Panel is a diagnostic tool designed to assess insulin resistance using serum samples. In India, insulin resistance underlies ~70-80 percent of type 2 diabetes (~77 million cases) and metabolic syndrome, common in urban/obese populations but underdiagnosed in rural/low-SES with prediabetes. High morbidity from delayed lifestyle intervention leading to progression to diabetes, NAFLD, CVD. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for fasting glucose, fasting insulin, HOMA-IR index, HOMA-Beta, and insulin sensitivity over 1-2 days with high accuracy, valuable for early detection in high-risk individuals. This diagnostic falls under metabolic screening and targets patients with obesity, acanthosis nigricans, or family diabetes, addressing accurate detection to guide diet/exercise or metformin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise insulin resistance assessment and reducing diabetes burden. Its serum-based approach ensures reliable calculation.**Other Names**: HOMA-IR Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: HOMA-IR standard; in India, used in diabetes clinics.**Purpose**: The test assesses 5 parameters including fasting glucose to guide insulin resistance evaluation, calculate HOMA-IR, inform intervention.**Test Parameters**: 1. Fasting Glucose, 2. Fasting Insulin, 3. HOMA-IR Index, 4. HOMA-Beta, 5. Insulin Sensitivity.**Pretest Condition**: Fasting 10-12 hours required; patients should report risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weight, family diabetes, acanthosis.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected insulin resistance including diabetes, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and calculate indices within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High HOMA-IR (>2.5-3) indicates insulin resistance, necessitating specialist input.**Specialist Consultation**: Diabetologists or endocrinologists should be consulted for management.**Additional Supporting Tests**: OGTT, HbA1c for confirmation.**Test Limitations**: Fasting-dependent; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Metabolic Studies India 2023. |
